Literature DB >> 2731181

Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.

N Caporaso1, R B Hayes, M Dosemeci, R Hoover, R Ayesh, M Hetzel, J Idle.   

Abstract

The risk of lung cancer in smokers was examined based on the debrisoquine metabolic phenotype and on exposure to occupational lung carcinogens, specifically asbestos and polycyclic aromatic hydrocarbons. Extensive metabolizers of debrisoquine are at a 4-fold increased risk for lung cancer compared to poor metabolizers, after adjustment for age, sex, and smoking (pack-years), when only occupationally unexposed subjects are considered. Increased risk related to the debrisoquine metabolic phenotype was greatest for squamous and small cell histologies, and least for the adenocarcinoma subtype. Men with a history of exposure to occupational carcinogens had significantly increased risk of lung cancer (relative risk = 2.8), after adjustment for age and smoking. Considering the combined effect of the high risk extensive metabolizers debrisoquine metabolic phenotype and likely occupational exposure to asbestos, the relative excess risk for lung cancer was 18-fold. This finding is consistent with a synergism in risk between the ability to extensively metabolize debrisoquine and occupational exposure to lung carcinogens in male smokers. Debrisoquine phenotyping has potential for identifying carcinogen-exposed workers at high risk of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731181

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990)

Authors:  N Caporaso; J R Idle
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

4.  N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.

Authors:  W Siegmund; J D Fengler; G Franke; M Zschiesche; O Eike; E Eike; P Meisel; R Wulkow
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

5.  Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.

Authors:  J Turgeon; W E Evans; M V Relling; G R Wilkinson; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

6.  Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors.

Authors:  M J Khoury; D K Wagener
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

Review 7.  Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism.

Authors:  E Jacqz-Aigrain; S Panserat; L Sica; R Krishnamoorthy
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

8.  Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.

Authors:  J M Ladero; J Benítez; J F González; E Vargas; M Díaz-Rubio
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.

Authors:  L B Anthony; T J Boeve; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer.

Authors:  M V González; V Alvarez; M F Pello; M J Menéndez; C Suárez; E Coto
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.